Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease.

  title={Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease.},
  author={Peter Lange and Bartolom{\'e} R. Celli and Alvar Agust{\'i} and Gorm Boje Jensen and Miguel J. Divo and Rosa Faner and Stefano Guerra and Jacob Louis Marott and Fernando D. Martinez and Pablo Mart{\'i}nez-Camblor and Paula M. Meek and Caroline A. Owen and Hans Petersen and Victor Pinto-Plata and Peter Schnohr and Akshay Sood and Joan B. Soriano and Yohannes Tesfaigzi and J{\o}rgen Vestbo},
  journal={The New England journal of medicine},
  volume={373 2},
BACKGROUND Chronic obstructive pulmonary disease (COPD) is thought to result from an accelerated decline in forced expiratory volume in 1 second (FEV1) over time. [] Key MethodMETHODS We stratified participants in three independent cohorts (the Framingham Offspring Cohort, the Copenhagen City Heart Study, and the Lovelace Smokers Cohort) according to lung function (FEV1 ≥80% or <80% of the predicted value) at cohort inception (mean age of patients, approximately 40 years) and the presence or absence of COPD…

Figures and Tables from this paper

Lung Function Trajectories Leading to Chronic Obstructive Pulmonary Disease as Predictors of Exacerbations and Mortality.

COPd developed through normal maximally attained FEV1 trajectory is associated with an increased risk of respiratory and all-cause mortality compared to COPD developed through low maximally attain FEV 1 trajectory.

Longitudinal decline in lung function: a community-based cohort study in Korea

Among Korean males, smoking accelerates lung function decline over time whereas smoking cessation slows the rate of FEV1 decline regardless of pre-bronchodilator airflow limitation, underscores the importance of smoking cessation in Koreans.

The Course of Lung Function in Middle-aged Heavy Smokers: Incidence and Time to Early Onset of Chronic Obstructive Pulmonary Disease.

The hypothesis that middleaged and heavy smokers with low baseline lung function and rapid LF decline trajectory have a high hazard ratio to develop COPD at an earlier time than smokers with other LF trajectories was tested.

Annual change in FEV1 in elderly 10-year survivors with established chronic obstructive pulmonary disease

The disease activity, which is often expressed as annualized change in FEV1, might be changeable either way over years in patients with established COPD.

Longitudinal Modeling of Lung Function Trajectories in Smokers with and without Chronic Obstructive Pulmonary Disease

Data‐driven analysis identifies four lung function trajectories in NAS with differing levels of maximum lung function and rate of decline and genetic contribution to these trajectories was associated with greater parental histories of COPD, decreased exercise capacity, greater dyspnea, and more frequent COPD exacerbations.

Prevalence, Characteristics, and Prognosis of Early COPD: The Copenhagen General Population Study.

Among individuals aged <50 years and ≥10 pack-years of tobacco consumption from the general population, 15% fulfil criteria of early COPD, and these individuals more often have chronic respiratory symptoms and severe lung function impairment, and an increased risk of acute respiratory hospitalisations and early death.

Lung function trajectories and chronic obstructive pulmonary disease: current understanding and knowledge gaps

A better understanding of lung function development and eventual decline in those atrisk for progression to COPD will aide in a precision medicine approach, in which markers for those at risk of low maximal lung function and accelerated decline are identified.

Lung function in adults and future burden of obstructive lung diseases in a long-term follow-up

An association between lung function and the future burden of lung diseases throughout 27 years of follow-up is found and adults with an FEV 1 /FVC: 70–75 need extra attention in the case finding.

Predictors of accelerated FEV1 decline in adults with airflow limitation—Findings from the Health2006 cohort

In individuals with preexisting AL, being female and having ever or current respiratory symptoms were associated with an accelerated annual decline in FEV1, although to a smaller extent, a steeper decline was also predicted by age, baseline FEV 1, waist/hip-ratio, and number of pack-years smoked.



Lung function decline in COPD

The present authors reviewed spirometric data of COPD patients included in the placebo arms of recent clinical trials to assess the lung function decline of each stage, defined according to the severity of airflow obstruction as proposed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines.

The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort.

The multidimensional evaluation of COPD should offer insight into response to COPD management and most patients show no statistically significant decline of FEV(1) or increase in BODE.

Changes in forced expiratory volume in 1 second over time in COPD.

The rate of change in FEV(1) among patients with COPD is highly variable, with increased rates of decline among current smokers, patients with bronchodilator reversibility, and patients with emphysema.

Early life origins of chronic obstructive pulmonary disease

People with early life disadvantage have permanently lower lung function, no catch-up with age but a slightly larger decline in lung function and a substantially increased COPD risk.

Variations in FEV1 decline over time in chronic obstructive pulmonary disease and its implications

  • D. Tashkin
  • Medicine
    Current opinion in pulmonary medicine
  • 2013
The wide distribution of individual rates of decline in FEV1 includes especially rapid and slow declines, and future research is needed to identify biomarkers that both are predictive of a rapid decline within individuals who might then be targeted for special intervention and might also serve as surrogate endpoints in interventional trials.

Combined effect of lung function level and decline increases morbidity and mortality risks

Risks of chronic obstructive pulmonary disease morbidity, COPD or coronary heart disease mortality, and all-cause mortality were estimated from combined effects of level and decline in forced expiratory volume in one second (FEV1), with significant increasing trends for mortality and in individuals with a baseline age ≤45.

Disease progression in young patients with COPD: rethinking the Fletcher and Peto model

It is suggested that younger individuals presenting with COPD develop the disease from an already compromised pulmonary and systemic status, complementing the model of steeper decline of lung function proposed by Fletcher and Peto.

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.

Pharmacotherapy with salmeterol plus fluticasone propionate, or the components, reduces the rate of decline of FEV(1) in patients with moderate-to-severe COPD, thus slowing disease progression.

Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease.

Inhaled triamcinolone does not slow the rate of decline in lung function in people with COPD, but it improves airway reactivity and respiratory symptoms and decreases the use of health care services for respiratory problems.